Baxter International Inc.’s Stock Price Drops to $18.47, Experiencing a 3.60% Dip in Market Value

Baxter International Inc. (BAX)

18.47 USD -0.69 (-3.60%) Volume: 11.55M

Baxter International Inc.’s stock price currently stands at 18.47 USD, experiencing a decrease of -3.60% this trading session with a trading volume of 11.55M. The stock has seen a significant drop YTD, with a percentage change of -36.66%, indicating a challenging period for BAX.

Latest developments on Baxter International Inc.

Baxter International Inc. has experienced significant stock price movements recently, with the company reporting sales below analyst estimates in its Q3 earnings, leading to a 13.5% drop in its stock. Despite beating Q3 earnings estimates, Baxter trimmed its annual outlook again, causing its stock to hit a 52-week low. The company’s stock price has been further affected by Citigroup lowering its price target and stock traders buying high volumes of put options. Investors are encouraged to lead a securities fraud lawsuit against Baxter International, while legal scrutiny and ongoing financial risks have contributed to losses and a downgrade by Argus Research. Overall, Baxter International faces uncertainty and challenges, with its stock price under pressure and facing legal heat.

Baxter International Inc. on Smartkarma

Analysts from Baptista Research on Smartkarma are closely monitoring Baxter International‘s performance. In their report titled “Baxter International’s Novum Infusion Pump – Will the Relaunch Ignite a Revenue Surge?”, the analysts lean towards a bullish sentiment. They highlight that Baxter’s second quarter 2025 earnings results showed solid financial performance but also challenges in certain sectors, such as Medical Products & Therapies and Pharmaceuticals. Despite a 4% growth in sales, the company’s overall performance remained at the lower end of expectations.

Another report by Baptista Research on Smartkarma titled “Baxter International Is Building A Tariff Defense Mechanism With Exemption & Sourcing Tactics But Will It Work?” also leans towards a bullish sentiment. The analysts note that Baxter’s Q1 2025 earnings results demonstrated robust performance with notable growth across its operating segments. Sales from continuing operations increased by 5%, exceeding initial projections of 3% to 4%. The positive performance was driven by contributions from all three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Baxter International has a positive long-term outlook. The company scores high in the Dividend category, indicating a strong ability to provide consistent dividends to its shareholders. Additionally, Baxter International scores well in the Value category, suggesting that the company’s stock may be undervalued compared to its intrinsic worth. However, the company’s scores in Growth, Resilience, and Momentum are lower, indicating potential areas for improvement in terms of future growth prospects, ability to withstand economic challenges, and stock price momentum.

Baxter International Inc. is a company that specializes in developing, manufacturing, and marketing products and technologies related to various medical conditions such as hemophilia, immune disorders, and kidney disease. Their products are utilized in a variety of healthcare settings including hospitals, dialysis centers, and research laboratories. With high scores in Dividend and Value, Baxter International shows promise for investors looking for a company with a strong dividend track record and potential undervaluation in the stock market. However, the company may need to focus on improving its Growth, Resilience, and Momentum scores to ensure long-term success and sustainability in the competitive healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma